Founders Financial Securities LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 8.4% during the third quarter, Holdings Channel reports. The institutional investor owned 25,378 shares of the company’s stock after purchasing an additional 1,970 shares during the quarter. Founders Financial Securities LLC’s holdings in Johnson & Johnson were worth $6,719,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. ERn Financial LLC boosted its stake in shares of Johnson & Johnson by 10.6% during the third quarter. ERn Financial LLC now owns 919 shares of the company’s stock valued at $243,000 after purchasing an additional 88 shares during the period. Crew Capital Management Ltd grew its holdings in Johnson & Johnson by 7.4% in the 3rd quarter. Crew Capital Management Ltd now owns 9,957 shares of the company’s stock worth $2,636,000 after acquiring an additional 686 shares during the last quarter. Choreo LLC increased its position in shares of Johnson & Johnson by 1.5% in the third quarter. Choreo LLC now owns 142,622 shares of the company’s stock valued at $37,758,000 after acquiring an additional 2,052 shares during the period. Blueprint Financial Advisors LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $2,793,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of Johnson & Johnson in the third quarter worth about $187,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 64,515 shares of company stock valued at $17,271,766. Company insiders own 0.16% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $273.39 on Friday. The company has a market capitalization of $658.13 billion, a price-to-earnings ratio of 41.42, a price-to-earnings-growth ratio of 2.70 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.02. The company’s 50-day moving average is $265.74 and its 200 day moving average is $246.94.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is presently 81.21%.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on JNJ. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research note on Wednesday, July 15th. TD Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. UBS Group set a $270.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Argus set a $300.00 target price on Johnson & Johnson in a research report on Wednesday, July 29th. Finally, Wells Fargo & Company lifted their price target on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $275.92.
Read Our Latest Stock Report on Johnson & Johnson
Key Johnson & Johnson News
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
- Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
- Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
- Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
- Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
- Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
- Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
- Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation
Johnson & Johnson Profile
Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.
Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
